Abstract: Women with HLA-B*44, HLA-B*51, or HLA-B*57 who were infected with the HPV16
E6 variant
L83V had an approximately four- to fivefold increased risk for cancer compared with controls (odds ratio [OR] = 3.5, 95% CI = 1.1-11.1, OR = 4.2, 95% CI = 1.19-14.69, or OR = 4.67, 95% CI = 1.2-18.6, respectively).